Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.

Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.

AIMS/HYPOTHESIS: The aim of the study was to examine the impact of statin or omega-3-acid ethyl esters 90 (omega-3 EE90; omega-3-acid ethyl esters 90 refers to a mixture of ethyl esters of n-3 fatty acids) on estimated cardiovascular disease (CVD) risk in community-based people with type 2 diabetes...

Descripció completa

Dades bibliogràfiques
Autors principals:	Holman, R, Paul, S, Farmer, A, Tucker, L, Stratton, I, Neil, H
Format:	Journal article
Idioma:	English
Publicat:	2009

Ítems similars

The effect of a brief action planning intervention on adherence to double-blind study medication, compared to a standard trial protocol, in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: a cluster randomised sub-study
per: Farmer, A, et al.
Publicat: (2016)

Economic evaluation of factorial trials: cost-utility analysis of the AFORRD 2x2x2 factorial trial of atorvastatin, omega-3 fish oil and action-planning
per: Dakin, HA, et al.
Publicat: (2020)

Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial.
per: Neil, H, et al.
Publicat: (2010)

Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: A randomised placebo controlled factorial trial
per: Neil, H, et al.
Publicat: (2010)

Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes.
per: Hartweg, J, et al.
Publicat: (2009)

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
per: Colhoun, H, et al.
Publicat: (2004)

Safety of atorvastatin in the collaborative AtoRvastatin diabetes study (CARDS)
per: Newman, C, et al.
Publicat: (2006)

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
per: Hitman, G, et al.
Publicat: (2007)

Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
per: Jae Hoon Kim, et al.
Publicat: (2022-08-01)

Omega-3 Fatty Acid Based Nanolipid Formulation of Atorvastatin for Treating Hyperlipidemia
per: Revathy Sreedhar, et al.
Publicat: (2019-06-01)

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
per: Newman, C, et al.
Publicat: (2008)

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
per: Colhoun, H, et al.
Publicat: (2005)

Atorvastatin and carnitine combination versus atorvastatin alone impacts on the lipid profile of haemodialyzed patients: A randomised clinical trial
per: Hamid Noshad, et al.
Publicat: (2018-12-01)

Chemopreventive effect of omega-3 polyunsaturated fatty acids and atorvastatin in rats with bladder cancer
per: Nahla E El-Ashmawy, et al.
Publicat: (2017-02-01)

Effect of atorvastatin on stroke in the collaborative atorvastatin diabetes study (CARDS): Factors predictive of the risk of stroke
per: Newman, C, et al.
Publicat: (2005)

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
per: Colhoun, H, et al.
Publicat: (2009)

Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.
per: Hartweg, J, et al.
Publicat: (2008)

Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.
per: Hartweg, J, et al.
Publicat: (2008)

Effect of atorvastatin on stroke in patients with type 2 diabetes: factors predicting the risk of stroke in the Collaborative Atorvastatin Diabetes Study (CARDS)
per: Hitman, G, et al.
Publicat: (2005)

Effect of atorvastatin in patients 65 years of age with type 2 diabetes: Subgroup analysis from the collaborative atorvastatin diabetes study (CARDS)
per: DeMicco, D, et al.
Publicat: (2005)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
per: Raikou, M, et al.
Publicat: (2007)

CAD/CAM robotics and factories of the future '90/
per: 473471 International Conference on CAD/CAM, Robotics, and Factories of the Future (5th: 1990: Norfolk, VA), et al.
Publicat: (1991)

MULTICENTER TRIAL OF MIGLITOL IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES
per: Stratton, I, et al.
Publicat: (1992)

Economic evaluation of factorial randomised controlled trials
per: Dakin, H
Publicat: (2015)

Blood glucose self-monitoring in type 2 diabetes: A randomised controlled trial
per: Farmer, A, et al.
Publicat: (2009)

Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial.
per: Farmer, A, et al.
Publicat: (2009)

Blood glucose self-monitoring in type 2 diabetes: a randomised controlled trial
per: AJ Farmer, et al.
Publicat: (2009-02-01)

Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial.
per: Farmer, A, et al.
Publicat: (2007)

EE news
Publicat: ([199)

Design, analysis and presentation of factorial randomised controlled trials
per: Little Paul, et al.
Publicat: (2003-11-01)

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
per: Colhoun, H, et al.
Publicat: (2002)

Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
per: Jankowski, J, et al.
Publicat: (2018)

Atrial nitroso-redox balance and refractoriness following on-pump cardiac surgery: A randomised trial of atorvastatin
per: Jayaram, R, et al.
Publicat: (2020)

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
per: Thomason, M, et al.
Publicat: (2004)

Statines in treatment of patients with diabetes mellitus: niche of atorvastatine
per: S. A. Urazgildeeva
Publicat: (2018-03-01)

FREQUENCY AND CORRELATES OF MYOPATHY IN PATIENTS WITH DIABETES TAKING ATORVASTATIN
per: Kamil Rehman Butt, et al.
Publicat: (2021-04-01)

EE profiling system /
per: Nur 'Aqilah Murid, et al.
Publicat: (2007)

Effect of atorvastatin on skeletal muscles of patients with knee osteoarthritis: Post-hoc analysis of a randomised controlled trial
per: Yuan Z. Lim, et al.
Publicat: (2022-08-01)

Effects of combined therapy with atorvastatin and polyunsaturated omega-3 fatty acids on lipid profile, lipoprotein-associated phospholipase A2 and thromboxane
per: G. F. Piksina, et al.
Publicat: (2010-10-01)

Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
per: Jankowski, J, et al.
Publicat: (2018)